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MEPicides: potent antimalarial 
prodrugs targeting isoprenoid 
biosynthesis
Rachel L. Edwards  1, Robert C. Brothers2, Xu Wang2, Maxim I. Maron3,8, Peter D. Ziniel4, 
Patricia S. Tsang5, Thomas E. Kraft1,9, Paul W. Hruz1,6, Kim C. Williamson3,4, Cynthia S. Dowd2 
& Audrey R. Odom John  1,7
The emergence of Plasmodium falciparum resistant to frontline therapeutics has prompted efforts 
to identify and validate agents with novel mechanisms of action. MEPicides represent a new class of 
antimalarials that inhibit enzymes of the methylerythritol phosphate (MEP) pathway of isoprenoid 
biosynthesis, including the clinically validated target, deoxyxylulose phosphate reductoisomerase 
(Dxr). Here we describe RCB-185, a lipophilic prodrug with nanomolar activity against asexual parasites. 
Growth of P. falciparum treated with RCB-185 was rescued by isoprenoid precursor supplementation, 
and treatment substantially reduced metabolite levels downstream of the Dxr enzyme. In addition, 
parasites that produced higher levels of the Dxr substrate were resistant to RCB-185. Notably, 
environmental isolates resistant to current therapies remained sensitive to RCB-185, the compound 
effectively treated sexually-committed parasites, and was both safe and efficacious in malaria-infected 
mice. Collectively, our data demonstrate that RCB-185 potently and selectively inhibits Dxr in P. 
falciparum, and represents a promising lead compound for further drug development.
Despite intense efforts in drug development and aggressive vector control programs, malaria remains a formida-
ble challenge to public health. According to recent estimates, malaria causes 212 million clinical cases and 429,000 
deaths each year, predominately in young children living in sub-Saharan Africa1. While five species of apicompl-
exan parasites of the genus Plasmodium cause human malaria, Plasmodium falciparum is the most deadly1. Due 
to pervasive drug resistance, P. falciparum treatment has become increasingly dependent on a single class of com-
pounds, the artemisinins. Substantial evidence suggests that the effectiveness of artemisinin-based combination 
therapies (ACTs) is waning, thus threatening global malaria control2–4. Novel, clinically validated drug targets that 
can be exploited for target-based optimization are urgently needed.
The methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis is a well validated but unexploited 
drug target present in most eubacteria and apicomplexan protozoa. In P. falciparum, the MEP pathway enzymes 
are apicoplast-localized, and data suggest that isoprenoid precursor biosynthesis may be the only essential func-
tion of the plastid organelle in blood stage parasites5, 6. The pathway is initiated by the condensation of pyruvate 
and glyceraldehyde-3-phosphate, and proceeds through a series of enzymatic reactions to produce isopentenyl 
pyrophosphate (IPP) and dimethylallyl diphosphate (DMAPP), which are used to synthesize downstream prod-
ucts. The enzymes of the MEP pathway are essential, as isoprenoids are required for numerous cellular processes 
including aerobic respiration, membrane stability, and protein prenylation7, 8. Importantly, humans employ an 
alternate route for isoprenoid generation, using instead the mevalonate pathway whose components lack simi-
larity to MEP pathway enzymes. Due to the essentiality of the MEP pathway in P. falciparum and the absence of 
mammalian homologs, compounds that specifically inhibit MEP pathway enzymes are highly desirable.
1Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA. 2Department of 
Chemistry, George Washington University, Washington, DC, USA. 3Department of Biology, Loyola University 
Chicago, Chicago, IL, USA. 4Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 5Tuberculosis 
Research Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA. 6Department of Cell 
Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA. 7Department of Molecular 
Microbiology, Washington University School of Medicine, St. Louis, MO, USA. 8Present address: Albert Einstein 
College of Medicine, Bronx, New York, USA. 9Present address: Roche Pharma Research and Early Development, 
Roche Innovation Center, Munich, Nonnenwald, Penzberg, Germany. Correspondence and requests for materials 
should be addressed to A.R.O.J. (email: aodom@wustl.edu)
Received: 18 July 2016
Accepted: 21 June 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 8400  | DOI:10.1038/s41598-017-07159-y
The first committed enzymatic reaction of the MEP pathway is catalyzed by 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (Dxr/IspC; E.C. 1.1.1.267), and considerable efforts have been made to effectively tar-
get this enzyme9–11. Dxr catalyzes the reductive isomerization of 1-deoxy-D-xylulose 5-phosphate (DXP) to 
2-C-methyl-D-erythritol 3-phosphate (MEP), using a divalent cation (Mg2+, Mn2+, or Co2+) and NADPH as a 
cofactor12. Chemical inhibition of Dxr in blood stage P. falciparum depletes cellular MEP metabolites, and ulti-
mately kills the parasites13. Further, Dxr is druggable, contains a high flux-control coefficient, and is one of only 
seven antimalarial targets that have been clinically validated9, 12, 14, 15. These data demonstrate the essentiality of 
the Dxr enzyme and its value as a therapeutic target to combat P. falciparum malaria.
The best-characterized antimalarial agent known to target Dxr is the phosphonic acid antibiotic fosmido-
mycin (FSM, FR-31564) (Fig. 1), a slow, tight-binding inhibitor with two modes of inhibition (competitive and 
noncompetitive)16–20. Data indicate that FSM directly inhibits the P. falciparum Dxr enzyme with a half-maximal 
inhibitory concentration (IC50) of 21–160 nM, and FSM is active against asexual P. falciparum21. Since the MEP 
pathway is absent in mammals, FSM is safe, with mouse and rat LD50 values of >11,000 mg/kg following oral 
administration22. Similarly, FSM is well tolerated in human patients23–26.
Unfortunately, the potency of FSM against whole parasites is relatively poor (published IC50 values range 
between 0.4 to 3.7 μM), and parasite clearance is slow with a mean clearance time of 44 ± 18 h (mean ± SD; clear-
ance defined as the time from treatment initiation until the first of two negative blood smears)21, 24. FSM also 
demonstrates several unfavorable pharmacokinetic properties, including a short serum half-life (1.87 h) and poor 
oral bioavailability (20–40%)23, 27. In addition, a substantial proportion of patients treated with FSM, in either 
monotherapy or in combination, suffer from recrudescent infections, likely due to suboptimal drug character-
istics24, 28. Despite these shortcomings, FSM partnered with piperaquine has been evaluated in Phase II clinical 
trials as a non-artemisinin-based combination therapy to treat acute P. falciparum malaria29, 30.
To build on its inherent safety and efficacy, but improve upon its potency and pharmacokinetics, we examined 
a series of compounds structurally-related to FSM31, 32. These compounds differ structurally from FSM in the 
degree of unsaturation, terminal acetamide and/or presence of a lipophilic diester. The diester, often used as a 
cleavable prodrug, is putatively cleaved, yielding the active phosphonate inhibitor10, 33, 34. Since these compounds 
were fashioned to specifically target the Dxr enzyme of the MEP pathway, we have termed members of this series 
MEPicides. The most active antimalarial MEPicide was RCB-185, bearing three structural differences compared 
with FSM: an unsaturated propylene linker, a terminal acetamide, and a dipivaloyloxymethyl (diPOM) ester 
(Fig. 1). In this work, we find that RCB-185 is a potent antimalarial agent that kills parasites through MEP path-
way inhibition intracellularly, and effectively treats malaria in mice. Taken together, our work demonstrates the 
antimalarial potential of RCB-185, and supports exploration of novel MEPicides as therapeutic agents.
Results
The MEPicide RCB-185 is a potent and specific inhibitor of asexual P. falciparum parasites. To 
evaluate the activity of the Dxr inhibitors against blood stage parasites, we treated asynchronous cultures of P. 
falciparum strain 3D7 with EU-131, ERJ-207, or RCB-185, and then quantified growth after 72 h35. While both 
EU-131 and ERJ-207 were active against asexual parasites (51.6 ± 3.9 nM and 202.8 ± 15.2 nM, respectively), RCB-
185 was the most potent compound with a mean half-maximal inhibitory concentration (IC50) = 18.3 ± 1.9 nM 
(Fig. 1 and Table 1). For comparison, the in vitro activity of RCB-185 is similar to that of the current first-line anti-
malarial agent artemisinin, which has an IC50 = 10.4 ± 1.6 nM against 3D7 parasites (mean ± SEM from >3 inde-
pendent experiments, data not shown). Furthermore, RCB-185 has a 50-fold improved IC50 value compared with 
the well-described Dxr inhibitor FSM [IC50 value of 1021.5 ± 77.8 nM (Fig. 1 and Table 1)] and is 28-fold more 
potent than the acetyl derivative of FSM, FR-900098 [IC50 value of 511.0 ± 50.4 nM (Fig. 1 and Supplementary 
Table S1)]. These data indicate that RCB-185 is a robust inhibitor of asexual parasite growth.
Figure 1. Dxr inhibitors tested against P. falciparum. Displayed are the structures and IC50 values 
(mean ± SEM) against P. falciparum strain 3D7 from 9 or more independent experiments.
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Since our data indicate that RCB-185 is substantially more active than FSM, we performed molecular dock-
ing experiments to understand how RCB-185 might have distinct interactions with the target enzyme Dxr. We 
docked ERJ-207, the active component of RCB-185, to the P. falciparum Dxr crystal structure (PDB 3AU8) in the 
apo form with NADPH and Mn2+ bound36. All predicted binding conformations of ERJ-207 interact with Dxr at 
the DOXP binding cavity, and three dominant conformations for ERJ-207 were observed (Fig. S1). These orien-
tations were similar to the conformations observed for FSM, and thus a unique binding mode appears unlikely to 
account for the potency of RCB-18537.
RCB-185 inhibits isoprenoid biosynthesis in P. falciparum. Malaria parasites treated with small mol-
ecules that specifically target apicoplast functions, including compounds that block MEP pathway enzymes, are 
chemically rescued if cultures are supplemented with the isoprenoid precursor IPP5, 38. To investigate whether the 
growth inhibition caused by MEPicide treatment is due to inhibition of IPP synthesis, we treated P. falciparum 
with compounds over a range of concentrations (1.2 nM–4606.4 nM) and evaluated for IPP-mediated growth res-
toration. As displayed in Fig. 2, 250 μM IPP supports growth of P. falciparum treated with RCB-185 at all concen-
trations tested. These data are similar to the chemical complementation observed in FSM- and FR-900098-treated 
parasites supplemented with IPP (Fig. 2; previously reported in ref. 5; Fig. S2). In addition, growth of P. falciparum 
treated with the less potent FSM-like compounds, EU-131 and ERJ-207, was also rescued by IPP supplementation 
(Fig. S2).
Cell line FSM IC50 (nM)
RCB-185 IC50 
(nM)
P. falciparum 3D7 (pan-
sensitive, lab adapted) 1021.5 ± 77.8 18.3 ± 1.9
P. falciparum 7G8 
(quinine, chloroquine, and 
pyrimethamine resistant)
1235.7 ± 188.7 46.7 ± 10.9
P. falciparum D6 (mefloquine 
resistant) 1339.5 ± 246.7 37.6 ± 10.0
P. falciparum D10 
(mefloquine resistant) 2184.0 ± 353.0 42.5 ± 11.5




837.0 ± 141.0 31.9 ± 1.0
P. falciparum IPC 5202 
(chloroquine and artemisinin 
resistant)
862.8 ± 247.5 21.1 ± 1.8
Human HepG2 cells n.d. >100,000
Table 1. RCB-185 is active against multidrug resistant P. falciparum.
Figure 2. Isoprenoid precursors rescue RCB-185-treated P. falciparum. P. falciparum strain 3D7 was treated 
with FSM (grey circles) or RCB-185 (black squares) at a range of concentrations and growth quantified by 
PicoGreen (Life Technologies) after 72 h, as previously described35. The downstream isoprenoid precursor 
IPP rescues both FSM and RCB-185-treated parasites (open shapes) indicating the fosmidomycin analog 
is a specific inhibitor of the MEP pathway in P. falciparum. Shown is a representative graph from 3 or more 
independent experiments.
www.nature.com/scientificreports/
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The chemical rescue of RCB-185-treated parasites indicates that the compound affects an apicoplast func-
tion, and strongly implicates isoprenoid biosynthesis as the specific target. As RCB-185 is an analog of FSM, 
we predicted that treatment of P. falciparum with the MEPicide would deplete pathway intermediates beyond 
its proposed target, Dxr. To directly quantify MEP metabolites from treated parasites, we employed a liq-
uid chromatography-mass spectrometry (LC-MS) method that measures cellular levels of key MEP pathway 
intermediates, including 1-deoxy-D-xylulose 5-phosphate (DOXP), 2-C-methylerythritol 4-phosphate (MEP), 
4-diphosphocytidyl-2-C-methylerythritol (CDP-ME) and 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate 
(MEcPP)13. Briefly, 3D7 parasites were treated + /- RCB-185 for 10 h and MEP pathway metabolite levels were 
measured by LC-MS/MS. As anticipated, our metabolic profiling data indicated there was no significant differ-
ence in the levels of DOXP, the substrate for P. falciparum Dxr, in RCB-185-treated cultures (Fig. 3). However, 
MEP pathway intermediates measured downstream of Dxr were greatly diminished in treated parasites. Both 
MEP and CDP-ME were below the limits of detection (asterisks; 12.5 ng/mL and 1.25 ng/mL, respectively)13, and 
levels of the most distal metabolite, MEcPP, were significantly reduced when compared to untreated parasites 
(p < 0.01) (Fig. 3). Specifically, P. falciparum treated with RCB-185 at 1x and 7.5x the IC50 value of 18.3 nM corre-
sponded to 3.0- and 5.7-fold reductions in MEcPP levels, respectively. Our metabolic data strongly suggest that 
RCB-185 inhibits the first committed step of isoprenoid biosynthesis through direct inhibition of Dxr.
To further interrogate whether our FSM-like compounds inhibit the MEP pathway, we evaluated its anti-
malarial efficacy against a P. falciparum strain that produces high levels of the Dxr substrate, DOXP, due to a 
mutation in the metabolic regulator HAD1 (PF3D7_1033400). Previous data indicate that an increase in the 
intracellular pool of DOXP impedes the competitive inhibition of Dxr by FSM, which results in FSM-resistant 
parasites39. We predicted that a surplus in cellular DOXP would promote MEPicide resistance by a mechanism 
analogous to the FSM and FR-900098 resistance displayed by had1 parasites (had1 parasites were 5.2- and 4.2-fold 
more resistant to FSM and FR-900098, respectively; Figs 4a and S3)39. Indeed, had1 parasites were 4.2-fold more 
resistant to RCB-185 with an IC50 = 76.5 ± 18.5 nM when compared to an IC50 = 18.3 ± 1.9 nM for WT parasites 
(p < 0.05, Fig. 4b). Importantly, RCB-185 sensitivity was restored if a WT copy of HAD1 was supplied in the 
mutant strain (IC50 = 26.0 ± 6.4; Fig. 4b). Similar results were obtained with EU-131 and ERJ-207, such that had1 
parasites were more resistant to the compounds than WT parasites (Fig. S3; had1 parasites were 8.0- and 3.3-fold 
more resistant to EU-131 and ERJ-207, respectively). These data indicate that, similar to FSM, MEPicides likely 
compete with cellular DOXP. Collectively, our results demonstrate that our novel inhibitors specifically inhibit P. 
falciparum growth through competitive inhibition of Dxr of the isoprenoid biosynthetic pathway. In particular, 
our data validate that the most potent compound RCB-185 elicits antimalarial activity via Dxr inhibition, without 
significant off-target toxicities.
RCB-185 is active against drug-resistant P. falciparum. A major threat to public health is the emer-
gence of P. falciparum resistance to current therapies, including the frontline agents artemisinin and its derivatives 
artesunate and artemether40. Thus, the discovery and development of new classes of antibiotics that maintain 
effectiveness against drug-resistant parasites is essential. To assess whether RCB-185 inhibits growth of resistant 
parasites, we obtained clinical isolates of P. falciparum that were resistant to quinine, chloroquine, mefloquine, 
sulfadoxine/pyrimethamine, and/or artemisinin. The isolates were treated with RCB-185 for 72 h and growth 
inhibition quantified as described35. As displayed in Table 1, the resistant strains were sensitive to RCB-185, 
and the IC50 values were only modestly different than WT (3D7) parasites [IC50 shift between WT and resistant 
strains ≤3-fold;41]. These data demonstrate the potential utility of MEPicides in combating drug-resistant parasite 
strains.
RCB-185 is active against P. falciparum parasites committed to gametocytogenesis. Antimalarial 
development efforts prioritize compounds that target a broad range of life cycle stages, including the sexual 
gametocyte stages of the parasite required for mosquito transmission42. Previous studies of the MEP pathway in 
Figure 3. RCB-185 inhibits the MEP pathway in P. falciparum. MEP pathway metabolites were compared 
between untreated (UNT) P. falciparum and parasites treated with RCB-185 at either 1x or 7.5x the WT IC50 
value of 18.3 nM. After 10 h treatment, cultures were saponin-lysed, and the pellets were analyzed by LC-MS/
MS. Displayed are the means ± SEM of the metabolite levels from 3 independent experiments. No statistically 
significant difference was denoted by n.s., and asterisks indicate metabolites that were below the limit of 
detection (CDP-ME below 1.25 ng/mL and MEP below 12.5 ng/mL).
www.nature.com/scientificreports/
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P. falciparum gametocytes indicate that MEP pathway intermediates are present and isoprenoid biosynthesis 
appears to be required for gametocyte development43. However, FSM has been found to be ineffective against 
gametocytes in multiple independent studies24, 44–46. To assess whether RCB-185 could inhibit growth of parasites 
committed to gametocytogenesis, asynchronous cultures were treated with N-acetylglucosamine (NAG), which 
eliminates asexually replicating P. falciparum. The sexually-committed parasites were then treated with RCB-
185 for 72 h at a range of concentrations (1 nM–5 μM). Parasites were stained with a mitochondrial membrane 
potential dye [MitoProbe DiIC(1)5] and viability assessed by flow cytometry. As displayed in Fig. 5a, trophozoite 
and schizont stage parasites committed to gametocytogenesis were susceptible to RCB-185, as treatments as low 
as 30 nM caused a drastic reduction in viability (4.3-fold reduction). To evaluate whether the MEPicides could 
inhibit mid-stage (II/III) or late-stage (III-V) gametocytes, we purified P. falciparum gametocytes and then treated 
the cells with compounds for 72 h (1 nM–5 μM). Parasites were stained and viability measured as before. Unlike 
the known gametocytocidal agent epoxomicin, MEPicides were inactive against stage II-V gametocytes, even at 
concentrations >250x the asexual IC50 values (Fig. 5b, Figs S4 and S5). Consistent with the flow cytometry data, 
Giemsa-stained blood smears confirmed that epoxomicin dramatically alters the integrity of late-stage gameto-
cytes, whereas RCB-185-treated gametocytes were unchanged (Fig. 5c and data not shown).
RCB-185 is potent, safe, and efficacious in a mouse model of malaria. Due to the potent anti-
malarial activity of RCB-185 against asexual P. falciparum in vitro, we then tested whether the compound could 
effectively treat asexual blood stages in a mouse model of malaria. Briefly, groups of female Swiss Webster mice 
were infected by intraperitoneal (i.p.) injection with 103 blood-stage P. berghei ANKA expressing luciferase. After 
two days post-infection, mice were dosed daily with vehicle, 20 mg/kg chloroquine, or 50 mg/kg RCB-185. Mice 
were treated for 5 days, and the parasite burden was quantified by measuring the luciferase signal intensity at 
7 days post-infection. As demonstrated by the vehicle control, the number of P. berghei parasites expands by 
several orders of magnitude after one week of infection (Fig. 6). Parasite numbers were dramatically reduced in 
mice administered the control therapeutic chloroquine, as the luciferase signal was below the limit of detection 
(designated by an asterisk). Notably, P. berghei-infected mice treated with RCB-185 had more than a 3-log drop in 
the parasite load when compared to the vehicle (p < 0.0001; Fig. 6). In addition, no adverse effects were observed 
in mice administered the MEPicide, suggesting the compound was well tolerated at the treatment concentration. 
This corroborates preliminary data that indicates RCB-185 is nontoxic to human cell lines (Table 1; HepG2 cells 
>100,000 nM) with a selectivity index >5000 (selectivity index calculated as the HepG2 cell IC50/P. falciparum 
3D7 IC50), and thus, is a valuable antimalarial agent47.
Discussion
New antimalarials are urgently needed, and PfDxr represents a promising essential, druggable, and 
parasite-specific target for antimalarial drug development. The well-characterized Dxr inhibitor FSM exhib-
its poor antimalarial potency and sub-par pharmacokinetic and pharmacodynamic properties23–25, 27, 28. 
Nevertheless, the successful use of FSM to treat uncomplicated malaria infections suggests that improved 
Dxr-targeting agents are likely to be of extremely high value24, 25. Here, we report the discovery and character-
ization of RCB-185, a potent and specific MEPicide antimalarial that targets P. falciparum Dxr. In our hands, 
the activity of RCB-185 (IC50 = 18.3 ± 1.9 nM; Table 1) rivals that of current first-line therapeutics (artemisinin 
IC50 = 10.4 ± 1.6 nM; chloroquine IC50 = 14.5 ± 0.9 nM; data not shown).
The MEPicide family of compounds were designed to inhibit bacterial and parasitic growth by targeting Dxr. 
Evidence strongly supports that RCB-185, and the related MEPicides EU-131 and ERJ-207, inhibit intracellular 
Figure 4. P. falciparum strains with high levels of the Dxr substrate DOXP confer RCB-185 resistance. 
Dose-dependent growth inhibition by FSM (a) or RCB-185 (b) was determined for the parental strain (3D7; 
closed circles, grey line), the FSM-resistant PfHad1 loss-of-function parasite strain (had1; open squares, 
black line), and the FSM-sensitive complemented strain (had1 + HAD1-GFP; closed squares, black line) 
as previously described35. For FSM, the parent strain has an IC50 = 1021.5 ± 77.8 nM, while had1 has an 
IC50 = 5348.1 ± 830.6 nM. For RCB-185, the parent strain has an IC50 = 18.3 ± 1.9 nM, while had1 has an 
IC50 = 76.5 ± 18.5 nM. Data (mean ± SEM) are representative of at least 3 independent biological replicates 
performed in duplicate.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 8400  | DOI:10.1038/s41598-017-07159-y
P. falciparum Dxr as predicted. First, growth of MEPicide-treated parasites is rescued by IPP supplementation, 
suggesting that the compounds inhibit the isoprenoid biosynthetic pathway and lack additional modes of action 
(Figs 2 and S2). Second, targeted metabolite analysis is consistent with Dxr inhibition, as metabolites beyond the 
proposed block are drastically reduced (Fig. 3). Finally, our data indicate P. falciparum parasites with elevated 
levels of the isoprenoid precursors, including DOXP, are more resistant to MEPicide treatment, as previously 
reported for FSM (Figs 4 and S3)39. Our data strongly suggest that, like FSM, MEPicides are competitive with the 
Dxr substrate, DOXP. Altogether, our studies demonstrate that these FSM-like compounds inhibit P. falciparum 
through direct Dxr inhibition, without substantial off-target effects, and that further investigation of the most 
active compound, RCB-185, as a novel antimalarial is justified. Importantly, having a therapy with a known, 
parasite-specific, and proven mechanism-of-action will facilitate future efforts to develop similarly structured 
analogs.
P. falciparum has developed resistance to all clinically used agents including the aryl aminoalcohols (quinine), 
aminoquinolines (chloroquine), aminoalcohols (mefloquine), antifolates (sulfadoxine and pyrimethamine), and 
endoperoxides (artemisinin)48. To subvert the development of resistance and augment the therapeutic lifetime 
of an antimalarial drug, entities should be chemically distinct and target novel cellular processes48. RCB-185 is 
based on a unique chemical scaffold, and the Dxr enzyme is not targeted by existing therapies. We expected that P. 
falciparum strains that are resistant to a wide range of antimalarial compounds would be susceptible to RCB-185. 
To this end, we tested RCB-185 against a battery of drug-resistant parasites. As predicted, no meaningful shifts 
in the IC50 values were detected between 3D7 and resistant P. falciparum treated with either FSM of RCB-185 
(Table 1; clinically relevant IC50 shift ≥ 3-fold,41). These data demonstrate that RCB-185 may be an effective tool 
for combating environmental isolates refractory to current treatments.
Data indicate that gametocytes contain detectable levels of MEP pathway intermediates, and isoprenoid prod-
ucts are essential for gametocytogenesis43, 49. Accordingly, the MEP pathway enzymes are promising targets for 
eliminating the sexual-stages of P. falciparum. Previous studies have shown that FSM lacks gametocytocidal activ-
ity44, 46, 50. We similarly found that the MEPicides were inactive against stage II-V gametocytes and suspect this 
may be due to defects in their cellular import51 (Fig. 5, Figs S4 and S5). However, our data suggest that RCB-185 
is active against sexually-committed trophozoites and schizonts, indicating that this novel antimalarial agent will 
have modest transmission-blocking activity (Fig. 5A). We anticipate that improving anti-gametocytocidal activity 
will remain an important goal during further development of the MEPicides44.
Figure 5. RCB-185 is active against sexually-committed P. falciparum parasites. (a) Gametocyte-committed 
trophozoites and schizonts were treated with RCB-185 (1 nM–5 uM) for 72 h and viability assessed by flow 
cytometry using the mitochondrial dye MitoProbe DiIC(1)5. Displayed are the means ± SEM from at least 2 
independent biological replicates. Asterisks denote RCB-185 treatments that were statistically different than 
untreated parasites (p < 0.01). (b) Stage III/IV/V gametocytes were purified on a Percoll gradient and then 
treated with 5 μM RCB-185 for 72 h. Parasites were stained with MitoProbe DiIC(1)5 and viability quantified by 
flow cytometry. 32.5 nM epoxomicin and 0.5% DMSO were used as positive and negative controls, respectively. 
While the well-characterized antimalarial agent epoxomicin efficiently kills mature gametocytes (p < 0.01), 
flow cytometry data indicate that RCB-185 lacks activity against mature gametocytes. Displayed are the 
means ± SEM from at least 2 independent biological replicates (c) Representative Giemsa-stained blood smears 
of parasites treated in (b) demonstrate that 5 μM RCB-185 is inactive against stage III/IV/IV gametocytes.
www.nature.com/scientificreports/
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While a number of FSM-inspired compounds have potent activity against P. falciparum grown in culture, few 
Dxr inhibitors have moved beyond preliminary in vivo evaluation52–58. Brücher et al. previously identified FSM 
derivatives that were potent against asexual parasites but disappointingly lacked in vivo efficacy in both the P. 
berghei and P. falciparum SCID mouse models of disease21. In contrast, RCB-185 represents a significant advance 
over prior Dxr inhibitors, as a superior agent both highly potent against cultured P. falciparum, as well as thera-
peutically effective in treatment of P. berghei-infected mice, with a dramatic reduction of viable parasites (>3 log 
reduction; Fig. 6). We speculate that the lipophilic moiety present in our compounds may aid in erythrocyte and/
or parasite membrane penetration or may prolong the plasma retention time of the compounds, which ultimately 
enhances their antimalarial activity.
Prior studies indicate that FSM and its acetyl derivative FR-900098 are well tolerated in rats and mice at high 
doses20, 22. In addition, several reports have shown that FSM is safe in human patients, and FSM is currently 
under evaluation in Phase II clinical trials23–26, 29. Since many structural features of RCB-185 are similar to FSM, 
we predict that analogs of RCB-185 will be safe for treating acute P. falciparum malaria. Our preliminary studies 
indicate minimal cellular toxicity and no grossly apparent toxicity in mice. Additional studies will be needed to 
carefully evaluate the safety profile of RCB-185, and likewise, assess the pharmacokinetic and pharmacodynamic 
properties of this novel antimalarial.
Figure 6. RCB-185 is efficacious in a mouse model of malaria. Groups of 5-7 Swiss Webster mice were infected 
with 103 P. berghei ANKA expressing luciferase via i.p. injection. On days 2–7, mice were dosed once per day 
with vehicle, 20 mg/kg chloroquine, or 50 mg/kg RCB-185. At 7 days post-infection, mice were imaged with an 
IVIS imager and the parasite burden quantified by luciferase signal intensity. Representative images are shown 
for each treatment condition (top), and the average luciferase signal intensity quantified for each treatment 
(bottom). Displayed are the means ± SD for each treatment group. The asterisk indicates the luciferase signal 
was below the limit of detection.
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Many important human pathogens employ the MEP pathway to synthesize isoprenoids for essential cellu-
lar functions, including Toxoplasma gondii, Mycobacterium tuberculosis, Escherichia coli, Yersinia pestis, and 
Pseudomonas aeruginosa. Due to the conservation of the MEP pathway enzymes, in particular Dxr, we antici-
pate that the MEPicides will have broad-spectrum activity. Indeed, we have previously found that RCB-185 has 
activity against M. tuberculosis31. Additional studies will be required to discern whether drug-like properties of 
the MEPicides, including penetration and efflux, can be enhanced to improve potency against a large array of 
pathogenic organisms.
Materials and Methods
P. falciparum culture. P. falciparum strains were obtained through the MR4 as part of the BEI Resources 
Repository, NIAID, NIH (www.mr4.org): 3D7 (wild-type, WT), K1 (MRA-159; chloroquine and sulfadoxine-py-
rimethamine resistant) deposited by D.E. Kyle59, 7G8 (MRA-152; quinine, chloroquine and pyrimethamine resist-
ant) deposited by D. Walliker60, D6 (MRA-285; mefloquine resistant) deposited by D.E. Kyle, D10 (MRA-201; 
mefloquine resistant) deposited by Y. Wu, and IPC 5202 (Cam3.IR539T; MRA-1240; chloroquine and artemisinin 
resistant) deposited by D. Ménard. A P. falciparum strain containing increased levels of MEP pathway metabolites, 
had1 (MRA-1257), and its isogenic complement, had1 + PfHad1-GFP (MRA-1258), were generated in strain 
3D7, as reported39. Parasites were cultured in a 2% suspension of human erythrocytes and RPMI 1640 (Sigma) 
medium supplemented with 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyru-
vate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 µg/mL gentamicin, and 0.5% Albumax (Gibco) at 37 °C, 5% 
O2/5% CO2/90% N2 atmosphere as previously described13, 61.
EU-131, ERJ-207, and RCB-185. EU-131 and ERJ-207 were prepared as described31, 32. RCB-185 was 
prepared using the method described previously31 with one modification. The final step is a debenzylation reac-
tion using boron trichloride to afford the target molecule, but at a particularly low yield (13%). We improved this 
reaction with the addition of radical scavenger pentamethylbenzene62 and the yield improved significantly to 50% 
(Fig. S6).
P. falciparum growth inhibition assays. Asynchronous P. falciparum cultures were diluted to 1% par-
asitemia and treated with inhibitors at concentrations ranging from 0.25 ng/mL–100 μg/mL. Growth inhibition 
assays were performed in opaque 96-well plates at 100 µL culture volume. After 3 days, parasite growth was quan-
tified by measuring DNA content using PicoGreen (Life Technologies) as described35. Fluorescence was meas-
ured on a FLUOstar Omega microplate reader (BMG Labtech) at 485 nm excitation and 528 nm emission. Half 
maximal inhibitory concentration (IC50) values were calculated by nonlinear regression analysis using GraphPad 
Prism software. For isopentenyl pyrophosphate (IPP) (Echelon) rescue experiments, 250 µM IPP was added to the 
appropriate wells for the duration of the experiment.
Sample preparation for mass spectrometry analysis. P. falciparum strain 3D7 was cultured at 37 °C 
in 30 mL volumes in 100 mm tissue culture dishes (Techno Plastic Products) at 4% hematocrit until >8% par-
asitemia. Cultures were synchronized until >75% of parasites were in ring stage growth and then treated with 
RCB-185 at 1x or 7.5x the 3D7 IC50 for 10 h. Cultures were then lysed with 5% saponin, the parasite pellets 
washed with 1x phosphate-buffered saline (PBS), and the pellets stored at −80 °C. Samples were extracted via 
addition of 600 μL of ice-cold extraction solvent [chloroform, methanol, and acetonitrile (2:1:1, v/v/v)] and two 
liquid nitrogen-cooled 3.2 mm stainless steel beads, followed by homogenization in the Tissue-Lyser II instru-
ment (Qiagen, Valencia, CA) at 20 Hz for 5 min in a cold sample rack. Ice-cold water (600 μL) was added, and 
samples were homogenized for an additional 5 min at 20 Hz. After centrifugation (14,000 rcf at 4 °C for 5 min), 
the polar upper phase was aspirated and lyophilized. Dried samples were dissolved in 100 μL water and analyzed 
by LC-MS/MS.
LC-MS/MS analysis. The 4000QTRAP LC-MS/MS system (AB Sciex) was used in multiple-reaction moni-
toring (MRM) mode using negative ionization. The detailed instrument configuration and compound-dependent 
parameters for isoprenoid precursors were as previously described13. LC separation prior to MRM detection was 
achieved by ion pair reverse-phase chromatography as described previously63, with 10 mM tributylammonium 
acetate (pH 5.1-5.5) used as the ion pair reagent and the following modifications: (1) RP-hydro 100 mm × 2.0 mm, 
2.5 μm high performance liquid chromatography column (Phenomenex), (2) flow rate of 0.14 mL/min, (3) solvent 
A of 10 mM tributylammonium acetate in 5% methanol, (4) binary LC gradient (20% solvent B (100% meth-
anol) from 0 to 2.5 min, 30% B for 12.5 min, 80% B for 5 min, and column equilibration for 5 min), and (5) 
autosampler injection volume of 20 μL. For deoxyxylulose 5-phosphate (DOXP) and methylerythritol cyclodi-
phosphate (MEcPP) metabolites, one-way ANOVA was used to test for significance (VassarStats). A t-test was 
used to test for significance between UNT and 1x RCB-185 cytidine diphosphate methylerythritol (CDP-ME) 
levels (VassarStats). A significance test was not performed for MEP, as its levels were below the limit of detection 
(12.5 ng/mL) for RCB-185-treated parasites.
Gametocyte assay. Cell culture. P. falciparum strain NF54 was grown in RPMI 1640 supplemented 
with 25 mM HEPES, 29 mM sodium bicarbonate (pH 7.3), 0.37 mM hypoxanthine, 5 μg/mL gentamicin (KD 
Biomedical, Columbia, MD), and 10% human serum (Interstate Blood Bank, Memphis, TN). To evaluate the 
effect of the compound on early gametocyte-committed parasites, cultures were set up at 0.2% parasitemia and 
5% hematocrit and fed daily with RPMI. When the parasitemia was between 7–10%, the asynchronous culture 
was used directly for the drug assay described below. To isolate stage II/III gametocytes, a 3% parasitemia/6% 
hematocrit culture was expanded during the daily feed by dilution with additional RBCs and media to 1% para-
sitemia and 3% hematocrit. When the culture reached ~10% parasitemia, N-acetylglucosamine (NAG, 60 mM) 
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was added for 3 days and then mid-stage gametocytes (stage II/III) were harvested by centrifugation on a 17% 
or 18% Nycodenz cushion (Accurate Chemical and Scientific Corporation, Westbury, NY). To isolate late-stage 
gametocytes (stage III-V), the gametocyte cultures were initiated at 0.2% parasitemia and 6% hematocrit. On 
the third day, the hematocrit was reduced to 3% by increasing the media added during the daily feed. Following 
NAG (50 mM) treatment on days 10–12 to eliminate asexual parasites, stage III/IV/V gametocytes were purified 
on a 65% Percoll gradient and returned to culture. The parasites were resuspended at 10% gametocytemia and 2% 
hematocrit the following day.
Drug preparation. A 96-well flat-bottom plate was prepared with 2x concentration of the test compound ranging 
between 10 μM to 0.002 μM in complete RPMI with 1% DMSO. Positive controls included epoxomicin (65 nM) 
and/or maduramicin (100 nM), while DMSO (1%) was used as a negative control. NAG was used to selectively 
eliminate asexually replicating parasites and to define the population of gametocyte-committed parasites. The 
different parasite preparations were added to individual wells at 2% hematocrit for a 1:1 dilution. The plate was 
gassed with 90% N2, 5% O2, 5% CO2, and incubated at 37 °C with compound for 72 h. Viability was assessed 
microscopically via Giemsa-stained thin smears and by flow cytometry as described below.
Flow cytometric analysis. Viability was assayed by flow cytometry using a membrane potential dye, MitoProbe 
DiIC1(5) [DiIC1(5); Thermo Scientific], which was previously described and validated by comparison with the 
oxidoreduction indicator alamarBlue64. Cells were resuspended at 0.1% hematocrit in 50 nM DiIC1(5) with buffer 
containing 1.67 mg/mL glucose, 8 mg/mL NaCl, 8 mM Tris-Cl (pH 7.4) in a 96-well V-bottom plate and incu-
bated at 37 °C in the dark for 20 to 30 min prior to analysis on an Accuri C6 flow cytometer (BD Biosciences). 
Uninfected RBCs incubated with DiIC1(5) and unstained P. falciparum parasites were used as controls to deter-
mine the threshold for DiIC1(5) (640-nm laser excitation and FL4 emission filter [675/25 nm])-positive, single, 
and intact cell populations by following the gating strategy of Malleret et al.65. Viability was calculated by deter-
mining the ratio of DiIC1 (5)-positive events in drug-treated samples compared to vehicle controls. One-way 
ANOVA was used to test for significance between the three treatment groups (VassarStats).
Drug testing against Plasmodium berghei asexual blood stages. In vivo testing of RCB-185 against intraeryth-
rocytic P. berghei parasites was performed by the Anti-Infectives Screening Core at NYU School of Medicine 
(OLAW: A3435-01). The study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol (140112-03) was 
approved by the Institutional Animal Care and Use Committee of New York University School of Medicine, which 
is accredited by the Association For Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC).
Briefly, groups of 5–7 female Swiss Webster mice weighing 25–30 g were infected via intraperitoneal (i.p.) 
injection with 103 transgenic P. berghei ANKA that express a fusion GFP (mutant 3) and firefly luciferase 
(LucIAV) fusion under the control of the constitutive eef1aα promoter that is stably integrated into the 230p 
locus (PbGFP-Luccon)66. Two days post-infection, mice were treated by i.p. injection with 50 mg/kg of the test 
compound RCB-185. 20 mg/kg chloroquine and 2% methyl cellulose, 0.5% tween-80 were used as positive 
and vehicle controls, respectively. Treatment continued once daily for 5 days. At 7 days post-infection, mice 
were administered 2.5% isoflurane via a nose cone, and once anesthetized, were injected i.p. with 150 mg/kg 
of D-Luciferin Potassium-salt (Goldbio) dissolved in PBS. Mice were imaged 5–10 min after the injection of 
luciferin with an IVIS 100 (Xenogen, Alameda, CA), and data acquisition and analysis were performed with 
LivingImage (Xenogen) to quantify the level of infection. To test for significance between vehicle- and RCB-
185-treated mice, a t-test was used (VassarStats).
HepG2 cytotoxicity assay. HepG2 cells were cultured at 37 °C with 5% CO2 in Dulbecco’s modified Eagle’s 
medium (DMEM) containing either glucose or galactose as carbon sources. Cells were seeded onto 96-well plates 
at 2 × 104 and allowed to adhere overnight. Compounds or controls were added in triplicate to the wells by a 
2-fold serial dilution method. After 24 h, cellular ATP concentrations, which are proportional to the number of 
viable cells, were determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) and the lumi-
nescence quantified via a Fluor Optima microplate reader.
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